Business Wire

BrandShield Launches ElectionShield Product to Protect Political Campaigns From Online Threats

Share

BrandShield, a leading provider of services from brand protection to online threat hunting, has today announced the launch of ElectionShield.

Developed to protect political campaigns around the World from threats, such as fraudulent fundraising sites; phishing; social phishing; and impersonation, ElectionShield will be officially launched at one the World’s leading cybersecurity events, the RSA Conference in San Francisco, on February 24 - 28, 2020. BrandShield is exhibiting at South Expo, Booth# 3119.

ElectionShield utilizes BrandShield’s market-leading technology to protect political campaigns and candidates from a growing range of online threats. These include social impersonation; fraudulent fundraising schemes; domain squatting; sale of unauthorized merchandise; fake social media content; phishing, social phishing and fake news. The last few years have seen a proliferation of fake social media content, in some cases using ‘deep fake’ video, designed to attack politicians. According to The Guardian1, at a US Senate intelligence committee hearing in May 2018, the Republican senator Marco Rubio warned that deep fakes would be used in “the next wave of attacks against America and western democracies”.

BrandShield can provide political candidates with the tools to monitor, detect and takedown these threats, through an AI-Based technology and online threat hunters team.

The new product brings BrandShield’s proven technology to the political sphere for the first time. Since 2013, BrandShield has provided services from brand protection to online threat hunting to a growing international blue-chip client base, including Fortune 500 and FTSE100 companies. By utilizing proprietary AI and big data-based technology, BrandShield automatically analyses content, web-metrics and many other data points, to detect and remove online threats.

The launch of ElectionShield comes as political campaigners are increasingly communicating with voters digitally, using advertising services bought from digital and social media companies like Facebook, Google, YouTube, Twitter or Instagram. This channel expansion exposes these campaigns to a growing number of online threats. The importance of engaging digitally with voters is highlighted by the increasing sums of money being spent by political campaigns. In the UK2, according to the Electoral Commission, 42.8% of total advertising spend in the 2017 election was digital, up from 0.3% in 2011. The 2020 US Election is expected3 to see $1.6 billion spent on digital video, mostly on Facebook and Google.

Yoav Keren, CEO, BrandShield, said: “Good campaigns that communicate with voters are central to well-run elections and referendums. In terms of online campaigning, the growing range of threats, such as social impersonation, social phishing, fraudulent fundraising and fake news, weakens people’s faith. Having been a political campaigner myself, I know how important it is to ensure this faith is maintained. I am delighted that we have been able to utilize BrandShield’s proven technology in the political arena. We look forward to working with campaigns around the World.”

1 https://www.theguardian.com/technology/ng-interactive/2019/jun/22/the-rise-of-the-deepfake-and-the-threat-to-democracy

2 https://www.electoralcommission.org.uk/who-we-are-and-what-we-do/changing-electoral-law/transparent-digital-campaigning/report-digital-campaigning-increasing-transparency-voters

3 https://www.politico.com/f/?id=0000016b-b029-d027-a97f-f6a95aca0000

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bob Huxford / Robin Tozer / Ian Silvera
BrandShield@newgatecomms.com
+44 (0)20 3757 6880

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye